Sentences with phrase «therapeutic factors at»

-LSB-...] offers a high level delineation of key differences between individual and group therapy, and the different therapeutic factors at work in the two -LSB-...]

Not exact matches

Actual results and the timing of events could differ materially from those anticipated in the forward - looking statements due to these risks and uncertainties as well as other factors, which include, without limitation: the uncertain timing of, and risks relating to, the executive search process; risks related to the potential failure of eptinezumab to demonstrate safety and efficacy in clinical testing; Alder's ability to conduct clinical trials and studies of eptinezumab sufficient to achieve a positive completion; the availability of data at the expected times; the clinical, therapeutic and commercial value of eptinezumab; risks and uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and uncertainties relating to the manufacture of eptinezumab; Alder's ability to obtain and protect intellectual property rights, and operate without infringing on the intellectual property rights of others; the uncertain timing and level of expenses associated with Alder's development and commercialization activities; the sufficiency of Alder's capital and other resources; market competition; changes in economic and business conditions; and other factors discussed under the caption «Risk Factors» in Alder's Annual Report on Form 10 - K for the fiscal year ended December 31, 2017, which was filed with the Securities and Exchange Commission (SEC) on February 26, 2018, and is available on the SEC's website at www.sfactors, which include, without limitation: the uncertain timing of, and risks relating to, the executive search process; risks related to the potential failure of eptinezumab to demonstrate safety and efficacy in clinical testing; Alder's ability to conduct clinical trials and studies of eptinezumab sufficient to achieve a positive completion; the availability of data at the expected times; the clinical, therapeutic and commercial value of eptinezumab; risks and uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and uncertainties relating to the manufacture of eptinezumab; Alder's ability to obtain and protect intellectual property rights, and operate without infringing on the intellectual property rights of others; the uncertain timing and level of expenses associated with Alder's development and commercialization activities; the sufficiency of Alder's capital and other resources; market competition; changes in economic and business conditions; and other factors discussed under the caption «Risk Factors» in Alder's Annual Report on Form 10 - K for the fiscal year ended December 31, 2017, which was filed with the Securities and Exchange Commission (SEC) on February 26, 2018, and is available on the SEC's website at www.sfactors discussed under the caption «Risk Factors» in Alder's Annual Report on Form 10 - K for the fiscal year ended December 31, 2017, which was filed with the Securities and Exchange Commission (SEC) on February 26, 2018, and is available on the SEC's website at www.sFactors» in Alder's Annual Report on Form 10 - K for the fiscal year ended December 31, 2017, which was filed with the Securities and Exchange Commission (SEC) on February 26, 2018, and is available on the SEC's website at www.sec.gov.

Therapeutic interventions build on existing strengths and protective factors in the child and family, and consider at its heart the welfare of the child and family.

«Our findings suggest that PRMT5 is a possible prognostic factor and therapeutic target for glioblastoma, and they provide a rationale for developing agents that target PRMT5 in this deadly disease,» says co-corresponding author Robert A. Baiocchi, MD, PhD, associate professor of medicine and a hematologist at the OSUCCC — James who is also collaborating on an Ohio State effort to develop a PMRT5 inhibitor.

A team of researchers at Mayo Clinic and The Scripps Research Institute in Florida have developed a new therapeutic strategy to combat the most common genetic risk factor for the neurodegenerative disorders amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and frontotemporal dementia (FTD).

In the 1980s, Dr. Kaufman's experience with gene transfer and engineering led him to become a founding scientist at Genetics Institute Inc., where he engineered mammalian cells for high - level expression of therapeutic proteins, such as clotting factors that are now used to treat individuals with hemophilia.

«Therapeutic manipulation of repair factors such as BRCA1 may ultimately be used to prevent neuronal damage and cognitive decline in patients with Alzheimer's disease or in people at risk for the disease,» says senior author Lennart Mucke, MD, director of the Gladstone Institute of Neurological Disease.

The staff at Butler Hospital understand the psychological, social, biological and medical factors that can complicate a serious mental illness and offer patients the best care in a supportive, therapeutic setting.

The phenomenal and consistent care, love, patience and support from all the core staff members and the support team at Inner Fire, the daily regular rhythm of scheduled activities and responsibilities, the regular schedule of sessions in a variety of therapeutic modalities, the physical outdoors activities, the peaceful beauty of the environment, the camaraderie and support among the seekers, the delicious, wholesome and therapeutic diet plus too many other factors to mention, all created a space for our daughter to slowly begin to trust and to find and discover herself.

The therapeutic dotential of dietary precursor modulation by a fish - oil - supplemented diet (n - 3 fatty acids), such as eicosapentaenoic acid (C20: 5,n - 3) and docosahexaenoic acid (C22: 6,n - 3) in the therapy of ulcerative colitis has been shown to result in a 35 % to 50 % decrease in neutrophil production of LTB4.28 Significant improvement in symptoms and histologic appearance of the rectal mucosa has been observed in several small series of patients with Crohn's disease and ulcerative colitis given fish oil at 3 to 4 g daily for 2 to 6 months in uncontrolled studies.29 However, a larger, randomized, double - blind trial comprising 96 patients with ulcerative colitis failed to reveal any benefit in remission maintenance or treatment of relapse on 4.5 g of eicosapentaenoic acid daily, despite a significant reduction in LTB4 synthesis by blood peripheral polymorphonuclear cells.30 It should be emphasized, however, that the anti-inflammatory actions of the fish oils, in addition to inhibition of LTB4, include suppression of IL - 1 and platelet activating factor synthesis and scavenging of free oxygen radicals.30 The impact of increased lipid peroxidation after fish oil supplementation should be considered when altering the n - 6: n - 3 fatty acid ratio.31 Antioxidant supplementation may be able to counteract the potentially adverse effects of n - 3 fatty acids.

In addition risk factors for the disease, complications of the disease, therapeutic options, breeding advice, and the on - going research efforts at Purdue University's Veterinary Teaching Hospital will be discussed.

The most important factor in the therapeutic relationship is the comfort and ease in which the client can share at their own pace.

Therapeutic interventions build on existing strengths and protective factors in the child and family, and consider at its heart the welfare of the child and family.

Different therapeutic factors are at work in group psychotherapy.

There is also the opportunity for much sub-study work looking in more detail at the secondary outcomes and investigation into the mediating and moderating factors influencing therapeutic outcome, as well as into the therapeutic process itself.